Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for environmental allergies (such as insect bites) and asthma.[1][2] Immunotherapy involves exposing people to larger and larger amounts of allergens in an attempt to change the immune system's response.[1]
Meta-analyses have found that injections of allergens under the skin are effective in the treatment of allergic rhinitis in children[3][4] and in asthma.[2] The benefits may last for years after treatment is stopped.[5] It is generally safe and effective for allergic rhinitis, allergic conjunctivitis, allergic forms of asthma, and stinging insects.[6] The evidence also supports the use of sublingual immunotherapy against rhinitis and asthma, but it is less strong.[5] In this form the allergen is given under the tongue and people often prefer it to injections.[5] Immunotherapy is not recommended as a stand-alone treatment for asthma.[5]
Side effects during sublingual immunotherapy treatment are usually local and mild and can often be eliminated by adjusting the dosage.[7]Anaphylaxis during sublingual immunotherapy treatment has occurred on rare occasions.[7]
Potential side effects related to subcutaneous immunotherapy treatment for asthma and allergic rhinoconjunctivitis include mild or moderate skin or respiratory reactions.[8] Severe side effects such as anaphylaxis during subcutaneous immunotherapy treatment are relatively uncommon.[8]
Discovered by Leonard Noon and John Freeman in 1911, allergen immunotherapy is the only medicine known to tackle not only the symptoms but also the causes of respiratory allergies.[9] A detailed diagnosis is necessary to identify the allergens involved.[10]
^ abAbramson MJ, Puy RM, Weiner JM (August 2010). "Injection allergen immunotherapy for asthma". The Cochrane Database of Systematic Reviews (8): CD001186. doi:10.1002/14651858.CD001186.pub2. PMID20687065.
^Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, et al. (August 2006). "Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials". Annals of Allergy, Asthma & Immunology. 97 (2): 141–8. doi:10.1016/S1081-1206(10)60004-X. PMID16937742.
^ abErekosima N, Suarez-Cuervo C, Ramanathan M, Kim JM, Chelladurai Y, Segal JB, et al. (March 2014). "Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review". The Laryngoscope. 124 (3): 616–27. doi:10.1002/lary.24295. PMID23832632. S2CID8796632.